TheraRadar

Philogen

Pre-Approval PRO BETA
38
Total Trials
2
Phase 3
20
Phase 2
11
Recruiting
299
Score

Pipeline by Phase

Phase 3
2
Phase 2
20
Phase 1
23

Therapeutic Focus

Glioblastoma Rheumatoid Arthritis Breast Cancer Locally Advanced Basal Cell Carcinoma Advanced Solid Tumor

Clinical Trials (38)

NCT03567889 Phase 3 RECRUITING

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

Started: 9/20/2018

NCT02938299 Phase 3 ACTIVE NOT RECRUITING

Neoadjuvant L19IL2/L19TNF- Pivotal Study

Started: 7/1/2016

NCT07227350 Phase 2 RECRUITING

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Started: 6/1/2026

NCT06284590 Phase 2 RECRUITING

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Started: 7/12/2024

NCT06336291 Phase 2 ACTIVE NOT RECRUITING

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

Started: 5/22/2024

NCT07228442 Phase 2 NOT YET RECRUITING

L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma

Started: 2/1/2026

NCT07227870 Phase 2 NOT YET RECRUITING

L19IL2/TNF in Patients With Basal Cell Carcinoma

Started: 2/1/2026

NCT07120984 Phase 2 NOT YET RECRUITING

A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma

Started: 1/30/2026

NCT04733183 Phase 2 ACTIVE NOT RECRUITING

Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

Started: 8/28/2020

NCT02270632 Phase 2 TERMINATED

A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX

Started: 10/1/2014

NCT02054884 Phase 2 TERMINATED

F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma

Started: 10/25/2013

NCT02076633 Phase 2 COMPLETED

Intratumoral Administration of L19IL2/L19TNF

Started: 12/1/2012

NCT01253096 Phase 2 COMPLETED

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

Started: 4/1/2010

NCT01055522 Phase 2 TERMINATED

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Started: 6/1/2008

NCT01125085 Phase 2 COMPLETED

131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors

Started: 10/1/2009

NCT06640413 Phase 1 RECRUITING

A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

Started: 10/31/2025

NCT04471987 Phase 1 RECRUITING

Safety and Early Signs of Efficacy of IL12-L19L19.

Started: 7/1/2020

NCT07245992 Phase 1 RECRUITING

A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis

Started: 1/1/2026

NCT04443010 Phase 1 RECRUITING

Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

Started: 1/20/2021

NCT07600554 Phase 1 RECRUITING

A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer

Started: 5/27/2026

NCT07566897 Phase 1 NOT YET RECRUITING

A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors

Started: 5/1/2026

NCT06840548 Phase 1 COMPLETED

A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer

Started: 4/16/2025

NCT06840535 Phase 1 COMPLETED

A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer

Started: 4/8/2025

NCT05622175 Phase 1 WITHDRAWN

Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment

Started: 3/31/2023

NCT05784597 Phase 1 COMPLETED

A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors

Started: 4/27/2023

NCT05304663 Phase 1 WITHDRAWN

Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression

Started: 6/1/2022

NCT02957019 Phase 1 TERMINATED

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Started: 7/31/2013

NCT02957032 Phase 1 TERMINATED

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Started: 4/13/2016

NCT03779230 Phase 1 COMPLETED

Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse

Started: 5/31/2019

NCT03207191 Phase 1 COMPLETED

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Started: 12/2/2016

NCT01134250 Phase 1 COMPLETED

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Started: 8/6/2008

NCT01213732 Phase 1 COMPLETED

Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma

Started: 10/1/2008

NCT02076620 Phase 1 COMPLETED

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Started: 1/16/2013

NCT02076659 Phase 1 COMPLETED

Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients

Started: 9/1/2011

NCT01240720 Phase 1 COMPLETED

A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer

Started: 9/1/2008

NCT01131364 Phase 1 TERMINATED

Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

Started: 6/1/2008

NCT01124812 Phase 1 TERMINATED

131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)

Started: 5/1/2010

NCT01242943 Phase 1 TERMINATED

Radioimmunotherapy With 131I-L19SIP in Patients With Cancer

Started: 11/1/2008

Drug Candidates

L19IL2 L19TNF L19IL2/L19TNF [177Lu]Lu-OncoFAP-23 IL12-L19L19 [68Ga]Ga-OncoCAIX F8IL10 [68Ga]Ga-OncoACP3 Daromun Adjuvant therapy
Activity Status: Active
Last Trial Started: 6/1/2026
Last Trial Ended: 11/28/2025
Trials (12 months): 8
Completed Trials: 13
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.